INTENDED AUDIENCE
This activity is designed for healthcare professionals who are involved in the clinical care of patients with IPF. This may include physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.
EDUCATIONAL OBJECTIVES
Upon successful completion of this educational activity, participants should be better able to:
- Recognize the heterogeneity, disease burden, and racial and ethnic disparities across interstitial lung disease (ILD) populations to support more equitable, timely, and risk-informed care.
- Differentiate idiopathic pulmonary fibrosis (IPF) and related ILDs from other causes of chronic respiratory symptoms by integrating clinical features, high-resolution imaging, and multidisciplinary diagnostic frameworks.
- Apply personalized, evidence-based strategies to optimize therapy, manage tolerability, and support long-term treatment persistence in IPF and progressive fibrosing ILD, including emerging oral, inhaled, and combination therapies.
- Integrate multidisciplinary care pathways, practical diagnostic algorithms, and patient-centered communication strategies to improve coordination, shared decision-making, and longitudinal ILD management.
AGENDA
6:00AM
Registration and Breakfast
6:15AM-7:30AM
- Introduction and How Well Do You Really Know ILD?
- ILD Is Not One Disease: Why Labels Fail and Patients Fall Through the Cracks
- The 9-Month Cough: When Should You Stop Treating and Start Referring?
- If We Have Treatments, Why Aren’t We Using Them?
- Precision ILD: Where Fibrosis Meets the Vasculature
- Q&A | What Will You Do Differently on Monday?
7:30AM
Adjourn
FACULTY
Steven D. Nathan, MD, FCCP
Schar Chair
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Kevin R. Flaherty, MD
Director, Interstitial Lung Disease Program
University of Michigan Health
Ayodeji Adegunsoye, MD, MSc, PhD, FCCP
Professor of Medicine
Scientific Director, Interstitial Lung Disease Program
University of Chicago Medicine